These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36622389)

  • 21. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
    Takada J; Dinavahi R; Miyauchi A; Hamaya E; Hirama T; Libanati C; Nakamura Y; Milmont CE; Grauer A
    J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NOTCH2 Hajdu-Cheney Mutations Escape SCF
    Fukushima H; Shimizu K; Watahiki A; Hoshikawa S; Kosho T; Oba D; Sakano S; Arakaki M; Yamada A; Nagashima K; Okabe K; Fukumoto S; Jimi E; Bigas A; Nakayama KI; Nakayama K; Aoki Y; Wei W; Inuzuka H
    Mol Cell; 2017 Nov; 68(4):645-658.e5. PubMed ID: 29149593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone Structural Characteristics and Response to Bisphosphonate Treatment in Children With Hajdu-Cheney Syndrome.
    Sakka S; Gafni RI; Davies JH; Clarke B; Tebben P; Samuels M; Saraff V; Klaushofer K; Fratzl-Zelman N; Roschger P; Rauch F; Högler W
    J Clin Endocrinol Metab; 2017 Nov; 102(11):4163-4172. PubMed ID: 28938420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report.
    Kaneuchi Y; Iwabuchi M; Hakozaki M; Yamada H; Konno SI
    Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Hajdu Cheney mutation sensitizes mice to the osteolytic actions of tumor necrosis factor α.
    Yu J; Canalis E
    J Biol Chem; 2019 Sep; 294(39):14203-14214. PubMed ID: 31371452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hajdu-Cheney Syndrome: A Systematic Review of the Literature.
    Cortés-Martín J; Díaz-Rodríguez L; Piqueras-Sola B; Rodríguez-Blanque R; Bermejo-Fernández A; Sánchez-García JC
    Int J Environ Res Public Health; 2020 Aug; 17(17):. PubMed ID: 32854429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
    Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
    Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in NOTCH2 in families with Hajdu-Cheney syndrome.
    Majewski J; Schwartzentruber JA; Caqueret A; Patry L; Marcadier J; Fryns JP; Boycott KM; Ste-Marie LG; McKiernan FE; Marik I; Van Esch H; ; Michaud JL; Samuels ME
    Hum Mutat; 2011 Oct; 32(10):1114-7. PubMed ID: 21681853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis.
    Ebina K; Etani Y; Tsuboi H; Nagayama Y; Kashii M; Miyama A; Kunugiza Y; Hirao M; Okamura G; Noguchi T; Takami K; Goshima A; Miura T; Fukuda Y; Kurihara T; Okada S; Nakata K
    Osteoporos Int; 2022 Aug; 33(8):1807-1813. PubMed ID: 35362725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progress and Current Status in Hajdu-Cheney Syndrome with Focus on Novel Genetic Research.
    Aida N; Ohno T; Azuma T
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Denosumab versus romosozumab for postmenopausal osteoporosis treatment.
    Kobayakawa T; Miyazaki A; Saito M; Suzuki T; Takahashi J; Nakamura Y
    Sci Rep; 2021 Jun; 11(1):11801. PubMed ID: 34083636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe osteoporosis in familial Hajdu-Cheney syndrome: progression of acro-osteolysis and osteoporosis during long-term follow-up.
    Leidig-Bruckner G; Pfeilschifter J; Penning N; Limberg B; Priemel M; Delling G; Ziegler R
    J Bone Miner Res; 1999 Dec; 14(12):2036-41. PubMed ID: 10620062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotype variability in Hajdu-Cheney syndrome.
    Regev M; Pode-Shakked B; Jacobson JM; Raas-Rothschild A; Goldstein DB; Anikster Y
    Eur J Med Genet; 2019 Jan; 62(1):35-38. PubMed ID: 29698804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
    Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hajdu-Cheney Syndrome: A Report on Successful Halting of Acro-osteolysis.
    Duraiswamy G; Ashraf M; Sambandam SN; Shanmugasundaram S
    JBJS Case Connect; 2021 May; 11(2):. PubMed ID: 34019492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations in NOTCH2 in patients with Hajdu-Cheney syndrome.
    Zhao W; Petit E; Gafni RI; Collins MT; Robey PG; Seton M; Miller KK; Mannstadt M
    Osteoporos Int; 2013 Aug; 24(8):2275-81. PubMed ID: 23389697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotypic presentations of Hajdu-Cheney syndrome according to age - 5 distinct clinical presentations.
    Graversen L; Handrup MM; Irving M; Hove H; Diness BR; Risom L; Svaneby D; Aagaard MM; Vogel I; Gjørup H; Davidsen M; Hellfritzsch MB; Lauridsen E; Gregersen PA
    Eur J Med Genet; 2020 Feb; 63(2):103650. PubMed ID: 30980954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study.
    Baek KH; Chung YS; Koh JM; Kim IJ; Kim KM; Min YK; Park KD; Dinavahi R; Maddox J; Yang W; Kim S; Lee SJ; Cho H; Lim SK
    Endocrinol Metab (Seoul); 2021 Feb; 36(1):60-69. PubMed ID: 33677928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis.
    Kashii M; Kamatani T; Nagayama Y; Miyama A; Tsuboi H; Ebina K
    Osteoporos Int; 2023 Mar; 34(3):563-572. PubMed ID: 36585509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.